Robert L. Diaz

Precision for Medicine (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

21h-index3.2kcitations93works1.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Degradation and Inhibitors(26), Chromatin Remodeling and Cancer(25), Lung Cancer Treatments and Mutations(22), RNA modifications and cancer(15), Epigenetics and DNA Methylation(10)

Publications93 total

Abstract 4716: Functional precision medicine: Uncovering high actionability in rare cancers beyond genomics
Cancer Research·2025
Association between ex vivo pharmacotyping of patient-derived tumor organoids and personalized therapeutic options for patients with biliary tract cancer.
Journal of Clinical Oncology·2025· 1 cited
Abstract 952: <i>Ex vivo</i> drug testing identifies a potentially effective drug in 94% of cases for 403 patients in 42 tumor types
Cancer Research·2024
Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma
Frontiers in Oncology·2024· 6 citedOpen Access
Extraordinary clinical response to ibrutinib in low-grade ovarian cancer guided by organoid drug testing
npj Precision Oncology·2023· 25 citedOpen Access
Abstract 3399: Tumor organoid based drug sensitivity testing in ovarian cancer identifies exceptional responders to targeted therapies
Cancer Research·2023
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Carla Grandori(28), Christopher J. Kemp(23), Rachele Rosati(20), Reid Shaw(17), Kay E. Gurley(15), Hallie A. Swan(14), Franz X. Schaub(13), Russell Moser(13), Elizabeth M. Swisher(11), Grace Durenberger(11), Shalini Pereira(10), Goldie Y.L. Lui(9), Lauren Appleyard(9), Tan A. Ince(8), Vijayakrishna K. Gadi(8), C. David Allis(7), Shogo Shigeta(7), Payel Chatterjee(7), Michele A. Cleary(6), Jeffrey Shabanowitz(6)